Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01705652 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT01705652 is a Phase 2 study that was terminated before completion, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 21 participants.
The verdict
NCT01705652, a Phase 2 study, was terminated before completion, sponsored by The University of Texas Health Science Center at San Antonio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of the study is to (1) to determine the rate of PSA decline (the number declining). Tissue will be obtained for ancillary studies and (2) to determine the number of patients with a PSA decline to \<1.0 ng/ml at 3 months in patients receiving Nexrutine® with standard radiation therapy. The Secondary Objective is to confirm the tolerability of this regimen. The Third Objective (Ancillary studies) is To evaluate the molecular response of Nexrutine®. Molecular response is defined as changes in the molecular pathways.
Interventions
- DRUG Nexrutine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-07 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01705652
The ClinicalTrials.gov registry entry for NCT01705652 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nexrutine is the first listed.
NCT01705652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01705652 about?
NCT01705652 is a clinical study titled "Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients". The purpose of the study is to (1) to determine the rate of PSA decline (the number declining). Tissue will be obtained for ancillary studies and (2) to determine the number of patients with a PSA decline to \<1.0 ng/ml at 3 months in patients receiving Nexrutine® with standard radiation therapy. Th...
What is the current status of trial NCT01705652?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2011-07. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01705652?
The interventions under investigation include: Nexrutine (DRUG).
Who is sponsoring clinical trial NCT01705652?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.